ISSN: 2321 – 0494


News Flash

NL-1-2014-LETTER-1 CELLS...

www.ijfstonline.org CELLS IN LIVING MICE 'REPROGRAMMED' TO EMBRYONIC-LIKE STATE S. Sharmilabanu.,(B.Pharm Final Year), Vels university. Stem cells Stem cells are undifferentiated biological...

Read more...

NL-1-2014-LETTER-2 -...

www.ijfstonline.org BETTER ACTION ON WARFARIN ON YOUNGER HEART FAILURE PATIENTS   By:  Dhulipala Sowmya.,(B-Pharm II year),Vels University Warfarin may be more beneficial than aspirin in...

Read more...

...

  www.ijfstonline.org EFFECTS OF POLLUTION ON HUMAN HEALTH By:Rohin kumar.,(B-Pharm I Year)Vels Uuniversity The overview of main health effects on humans from some common types of pollution....

Read more...

NL-1-2014-LETTER-4...

www.ijfstonline.org PROGERIA By:  Prithivi Logathasan,(B-Pharm III Year),Vels University HGPS (Hutchinson-Gilford Progeria Syndrome) or Progeria is an extremely rare, fatal genetic condition....

Read more...

NL-1-2014-LETTER-5...

www.ijfstonline.org OBESE MADE LEAN BY LEANS By:  S.Santhya.,(B-Pharm-Final Year)Vels University The Microbes from Lean People Act as Anti-Obesity Agents. Bugs that lurk in the guts of slim...

Read more...

User Login



I2OR index

Who's Online

We have 8 guests online
Home Newsletters NL-1-2014-LETTER-18-FDA Approves Inhaled Insulin for Diabetes-P.Maheshwari
NL-1-2014-LETTER-18-FDA Approves Inhaled Insulin for Diabetes-P.Maheshwari PDF Print E-mail

www.ijfstonline.org

FDA Approves Inhaled Insulin for Diabetes

P.Maheshwari*, V.Ravichandiran, B.Senthilnathan

School of Pharmaceutical Sciences, Vels University, India

Email- This e-mail address is being protected from spambots. You need JavaScript enabled to view it

June 27, 2014 -- The FDA has approved inhaled insulin to treat type 1 and type 2 diabetes.

The insulin, called Afrezza, is a rapid-acting insulin and is meant to be taken at mealtime or soon after.

“Today’s approval broadens the options available" for delivering insulin in people with diabetes, Jean-Marc Guettier, MD, director of the FDA's Division of Metabolism and Endocrinology Products, says in a news release.

The FDA estimates that 18.1 million people have diabetes. About 7 million more are undiagnosed, the agency says.

This is the third time the drug was up for FDA approval. Its maker, MannKind Corporation, conducted additional safety studies after the first two attempts.

Patients with type 1 diabetes will need to use the drug in combination with long-acting insulin. Patients with type 2 diabetes will use it in combination with oral medications.

Afrezza carries a warning as it may cause a sudden tightening of the chest.  It is not recommended for people with asthma or COPD. It is also not recommended for people that smoke or for the treatment of diabetic ketoacidosis.

"Our expectation is it should be priced comparably to current fast-acting insulins delivered in pen form," says Matthew Pfeffer, a spokesman for MannKind.


 

Latest News

Popular

Indexing

News Letter


© 2012 Internationaljournalofindiansciences.org. All Rights Reserved. Powered by JK Webdesigns.

Free Counters